Using triptans for migraine during pregnancy does not increase risk of neurodevelopmental disorders in offspring
Prenatal exposure to triptans—alone or in combination with other migraine medications—does not increase the risk of developmental disorders in children up to age 14, according to research published in Neurology. The study is based on data from more than 26,000 pregnancies in a national registry in Norway and includes autism spectrum disorders, language disorders, and attention deficit hyperactivity disorder, among other diagnoses.